vTv Therapeutics
VTVT
42 hedge funds and large institutions have $10.3M invested in vTv Therapeutics in 2021 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 20 reducing their positions, and 14 closing their positions.
0.03% less ownership
Funds ownership: 0.21% → 0.18% (-0.03%)
13% less funds holding
Funds holding: 48 → 42 (-6)
25% less capital invested
Capital invested by funds: $13.8M → $10.3M (-$3.5M)
43% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 14
45% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.41M |
| 2 |
Millennium Management
New York
|
+$714K |
| 3 |
HF
HRT Financial
New York
|
+$616K |
| 4 |
D.E. Shaw & Co
New York
|
+$460K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$241K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
-$2.1M |
| 2 |
BlackRock
New York
|
-$958K |
| 3 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$909K |
| 4 |
Two Sigma Investments
New York
|
-$582K |
| 5 |
State Street
Boston,
Massachusetts
|
-$477K |
VTVT Hedge Fund Activity: Q2 2021 in Review
42 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q2 2021, worth a combined $10.3M — down 25% from $13.8M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of VTVT and 8 opened new positions — a net loss of 6 holders — while 20 trimmed existing stakes and 11 added.
The largest buyer was Vanguard Group, adding an estimated $2.41M. The largest seller was Nuveen, exiting entirely with an estimated $2.1M sold.
- 42 institutional investors held vTv Therapeutics (VTVT) as of Q2 2021, down from 48 in Q1 2021.
- Funds reported $10.3M of vTv Therapeutics stock for Q2 2021, down 25% quarter-over-quarter.
- 8 funds opened new vTv Therapeutics positions in Q2 2021 and 14 closed out, a net change of -6 holders.
- The largest vTv Therapeutics buyer in Q2 2021 was Vanguard Group, an estimated $2.41M added.
- The largest vTv Therapeutics seller in Q2 2021 was Nuveen, an estimated $2.1M sold.
Based on aggregated 13F filings for Q2 2021.